This article identifies and discusses the contribution of information and communication technologies (ICTs) to the technological cooperation projects of Bio-Manguinhos, a pharmaceutical manufacturer that belongs to Osvaldo Cruz Foundation (FIOCRUZ), responsible for producing vaccines, reagents and biopharmaceuticals, with priority on meeting the needs of the Brazilian public health system. It is a case study with a qualitative approach for descriptive and explanatory purposes. The data were collected from 14 interviews conducted with managers of research and development (R&D) projects with high relevance to the organization. The results allow concluding that the ICTs requiring greater interdependence between partners and two-way knowledge flows have not yet been used. They also show the importance of closer cooperation between the information technology (IT) and R&D areas. A future positioning of Bio-Manguinhos as a technological center focused on discovery and sale of new active ingredients can favor the use of tools that promote greater integration between the partners of technology cooperation networks.
INTRODUCTION
key characteristic of the chemical companies that gave rise to today's pharmaceutical firms was control of all the steps of the productive chain, including the structuring of professional research and development (R&D), aimed at the creation and protection of intellectual property (IP) .
The logic for generating revenue of the large global pharmaceutical companies formerly was to keep the intangible assets, consisting of the knowledge generated in the pharmacology and chemical synthesis processes, i.e., the IP, internal until the active ingredients discovered in the experiments could be converted into new drugs with patent protection. This logic was called by Chesbrough (2010, p. 356 ) the "blockbuster business model."
The advent of modern biotechnology, involving the use of genetic engineering, molecular biology and biochemistry to discover and produce drugs, has dramatically changed the process of technological innovation in the pharmaceutical industry (CHIARONI; CHIESA; FRATTINI, 2008; MALERBA; ORSENIGO, 2001) . In face of the rising costs and long time frames, partly caused by stricter regulatory requirements, and in face of the impossibility of detaining all the knowledge involved in scientific discoveries in molecular biology, technological cooperation network arrangements and open R&D management models are coming to the fore in the pharmaceutical industry (POWELL et al., 2005;  HUGHES; WAREHAM, 2010).
Molecular biology, especially experiments into the structure and function of genetic material and their expression products, proteins, is a field of knowledge that has particularly relied on the intensive use of computers starting in the 1960s (CATANHO; MIRANDA; DEGRAVE, 2007) .
With the preponderance of collaborative models, studies carried out since the mid-1990s have brought evidence of the growing importance of information and communication technologies (ICTs) to the management of the information produced by the R&D process ROTHWELL, 1994) . Research has also indicated that ICTs contribute to the virtualization of the innovative process itself, reducing the duration and costs of R&D projects (DOGSON; GANN; PITASSI, 2012; THOMKE, 2003; VERONA; PRANDELLI; SAWHNEY, 2006) Foundation (FIOCRUZ) that is responsible for producing vaccines, reagents and biopharmaceuticals, targeted with priority to meet Brazilian public health demands.
THEORETICAL FRAMEWORK

TECHNOLOGICAL INNOVATION IN PHARMACEUTICAL ORGANIZATIONS
The biotechnology revolution has required pharmaceutical organizations to acquire key knowledge in molecular biology to conduct their R&D projects (MALERBA; ORSENIGO, 2001 ). In molecular biology, studies of the possible causes of the malfunctioning of the information transmitted by DNA gave rise to research into genomics, which analyzes genetic sequences to quantify the expression of genes in cells; proteomics, which involves experiments to identify the structure of proteins and their functions in living organisms; and molecular dynamics, which simulates the physical movements of atoms and molecules (OSTROWSKI; WYRWICZ, 2009). Chiaroni, Chiesa & Frattini (2008) formulated a model, which we adopt in this study, to depict the typical R&D process that currently predominates in the pharmaceutical industry.
Below we present a brief description of each step shown in Figure 1 , as summarized by Oliveira (2011, p. 35-36) . We have included additional references to deepen understanding of ideas developed in the steps of this model. The aim of the first step of the R&D process is to identify the gene, protein or sequence of both that lies at the base of the pathogen causing a target disease. The second step involves study of the gene or protein identified seeking to understand its interaction with the organism as a whole and to check, by accessing public databases, the possible existence of IP rights over any substance used in the product targeted for development. A more detailed discussion of the techniques and tools applied in these initial phases can be found in Bare et al. (2010) .
After evaluating the genetic base of the disease's evolution, it is necessary to identify a compound that has the desired effects in treating this disease. This compound is the active ingredient of the future drug. The optimization phase adds to this compound the other substances to be included in the drug formulation, aiming to protect, support and enhance the stability of the active ingredient and increase the patient's response to the medicine.
The pre-clinical tests investigate the effects, especially on animals (in vivo testing), of the mechanisms of absorption, distribution, metabolism, excretion and toxicity of the new drug. Before entering the clinical testing phases, it is necessary to obtain initial approval from the competent governmental agencies.
The clinical tests, with direct involvement of human patients, are carried out in three phases. In the first, the new drug is tested on a small group (20 to 80) of healthy people to assess its safety and determine the adequate dosage. In the second, the drug is tested on a larger group of people (100-300) affected by the disease of interest to evaluate the drug's effectiveness and determine the common short-term side effects and possible risks of its use.
In the third phase, the sample of patients is enlarged (1000-3000) to confirm the drug's efficacy and assess the cost-benefit relation of its application. If these three phases are successful, the regulatory authority will approve the drug for sale.
The fifth and last step of the process entails the activities complementary to the purchase, production, logistics, marketing and sale of the new drug. It also involves postmarketing tests of the drug's performance throughout its life cycle, for the purpose of measuring additional risks and benefits. Bastos (2005) presents more details of the pattern of technological innovation in the current pharmaceutical industry. An interesting discussion of the interdependence of the initial phases of scientific research and the other downstream activities of the innovation process in the pharmaceutical industry can be found in Malerba & Orsenigo (2001) . Finally, the seminal article of Teece, Pisano & Shuen (1997) sheds more light on the importance of mastering the marketing steps to generate appropriate value in the creation of new drugs.
TECHNOLOGICAL COOPERATION NETWORKS
As pointed out by Oliveira (2011) , establishing more open R&D structures is not a new argument, disconnected from the evolution of the capitalist economy during the twentieth The image of the organization as a living organism in permanent interaction with its ecosystem has been explored in the organizational ecology literature (HANNAN; FREEMAN, 1977) . The understanding that the firm is embedded in social relations with other organizations also contributed to shift the focus of analysis from the firm in isolation (UZZI, 1997). The constructs brought by embeddedness strongly influenced the vision of networks in various fields of study, especially strategy (DYER; SINGH, 1998; GULATI, 1998; JARRILLO, 1998) . The construction of networks (GOMES-CASSERES, 1996) and establishment of strategic alliances (NOOTEBOON, 1999) started to be seen as effective mechanisms for access to external sources of knowledge that could be applied in the innovation process.
From the perspective of distributed capabilities (COOMBS; METCALFE, 2000), networks use organizational routines that allow each partner to complement the knowledge necessary to generate and disseminate new products and processes, using purposeful specialization and multidirectional flows to transfer knowledge between partners. According to Dantas & Bell (2009, p. 831) , learning and innovation networks (LIN) are " [...] organizational arrangements that involve actors with different capabilities and that are concerned with knowledge flows and the coordination of learning and innovation."
As pointed out by Laursen & Salater (2006) , recognition of the importance of external ties for firms' innovative performance does not mean the absence of factors that condition the effectiveness of collaborative networks. This results from the cognitive difficulty of dealing with an excessive number of partners and technological paths. In line with this argumentation, Pisano & Verganti (2008) state that the type of collaboration with external partners depends on the maturity of the knowledge sought. Figure 2 describes the typology proposed by Pisano & Verganti (2008) , which we adopt in this study. Then we present a brief description of the objectives and mechanisms that enable each type of collaboration of the model, as presented by the authors of the original article and summarized in Oliveira (2011, p. 38-40) . This model involves aspects of governance and the degree of openness of the cooperation networks, discussed in more detail by other authors associated with the economics of innovation and management of innovation. We add new references to allow the reader to delve more deeply into the ideas in question. In the innovation mall, the company receives a large number of solutions regarding scientific domains that can go beyond its knowledge or experience, but it still wants to maintain control over the direction of the innovation process. This mode is recommended when the company detains the key knowledge and wants to maintain the integrity of a system, using the network to accelerate the development of less complex incremental innovations. For more details about the types of incremental or radical innovation, see Sivadas & Dwyer (2000) . The biggest challenge is to attract many ideas from various fields of knowledge, examine them systematically and choose the most suitable direction. Huston & Sakkab (2006) discuss the impact of R&D resulting from connection to technology markets. The mechanisms that enable this mode are: i) the ability to understand the needs of customers and to test and examine solutions at acceptable costs (a summary of experimentation processes can be found in Thomke [2003] ); ii) the capacity to design systems that break down large problems into discrete parts so that each partner can work autonomously, for subsequent integration by the company; and iii) the use of information platforms that facilitate dynamic collaboration. Pitassi (2012) contains a deeper discussion of virtual collaboration networks.
In the innovation community, usually associated with open source code movements, any company or partner can propose problems or offer specific solutions with a well-defined outline. The interaction between joining open code communities and following competitive or open technology strategies is covered in Chesbrough & Appleyard (2007) . This mode is recommended when the firm can use the knowledge generated in the network to improve its In the consortium, no one firm alone masters all the fields of knowledge potentially involved in the solution. Mutual dependence and multiple directions of knowledge exchange discourage attempts at control over capture of the value generated by the innovation (this is one of the central arguments in favor of adopting an open innovation strategy in the vision of ). It is recommended in situations where research involves high costs and risks, so all partners can divide the costs and rewards of the particular innovation. The greatest challenges are to identify the underlying knowledge and the partners that are best qualified and to influence the direction of innovation to obtain contributions that will be profitable for 
Grid information technology
To coordinate the use of distributed computational resources in multiorganizational scientific experiments. 
High throughput screening
To accelerate the discovery of drugs by means of the association of sophisticated computer programs for control, robotics, optics, instruments for manipulation of liquids and visualization.
Chen ( 
Tele-interaction
To enable the exchange of information, provision of services and interaction of virtual teams of researcher, to overcome barriers of time and space. Hebert et al. (2006) Virtual prototyping, simulation and optimization
To create virtual prototypes, products and productive processes. 
Toolkits for clients
To offer user-friendly IT tools to clients and partners to enable them to participate in the development of new products.
Nambisan (2002) 
Source: Prepared by the authors.
METHODOLOGY
The survey described in this article sought to understand, in the opinion of the scientists who work in the R&D areas, the contribution of ICTs to the technological collaboration projects of pharmaceutical organizations, which explains the choice of a qualitative approach (DENZIN; LINCOLN, 2000) .
The primary unit of analysis (YIN, 1994) was the technological collaboration projects of Bio-Manguinhos indicated by the office of the vice-presidency for technological development. This study is both descriptive (VERGARA, 2007) , with the purpose of identifying the types of ICTs used, and explanatory, because we discuss how these ICTs are used in the projects and their contribution to the intended objectives.
With respect to the means, this is a single case study. The use of single case studies is appropriate in emblematic cases (YIN, 1994; STAKE, 1995) . We chose Bio-Manguinhos because it is considered a benchmark in Brazil in the production of vaccines and diagnostic kits, and it has relied heavily in recent years on cooperation with other entities to accelerate its technological innovation.
The research subjects were 14 scientists involved in the R&D area: the vice-director of the technological development area, responsible for the R&D center; project managers; program managers; the project office manager; IT manager; information security manager;
and manager of the Laboratory for Monoclonal Antibody Technology (LATAM).
Besides the interviews, we gathered data from published articles and organizational documents. The interviews were conducted between April 2011 and March 2012. Personal observation of participants is seen as an essential source of data (CHECKLAND, 1991) . In this case, one of the authors is the manager of the IT area of Bio-Manguinhos, with first-hand familiarity with the IT projects in support of the R&D area. The interviews were supported by a script and were recorded with the prior authorization of the respondents. The data collected were treated by applying categorical content analysis (BARDIN, 1979) . Classification of the ITC used in the collaboration strategy 1) Automatic sequencer with a sequencing analysis system; 2) Real-time PCR with a system to interpret data and generate results; 3) Automation of pipetting; 4) Technology to extract nucleic acid; 5) High throughput screening; 6) PubMed portal; 7) GenBank sequences bank; 8) Teleconference.
PRESENTATION AND DISCUSSION OF THE RESULTS
Delay of the process 1) Videoconference tool in the premises of Bio-Manguinhos; 2) System to store and exchange data with partners.
Agile consultation of information.
1) Web tools for virtual collaboration; 2) Computational systems for experimentation; 3) Virtual participation and visualization; 4) Tele-interaction; 5) High throughput screening; 6) Laboratory information management system; 7) Virtual knowledge brokers; 8) Portal of the company with functionalities to support innovation.
1) Teleconference;
2) PubMed portal; 3) GenBank sequences bank; 4) Genomic sequencing; 5) Analysis of sequencing; 6) Encrypted email; 7) System to record meeting minutes, data and results of analyses (of the partner); 8) Gotomeeting for videoconference (of the partner)
Delay of the process 1) LIMS integrated with EPM;
2) Use of SharePoint for exchange with external partners.
1) Avoids the need for travel to branch of partner;
2) Retention and sharing of information.
1) Web tools for virtual collaboration;
2) Computational systems for experimentation; 3) Virtual participation and visualization; 4) Tele-interaction; 5) Laboratory information management system; 6) Virtual knowledge brokers; 7) Portal of the company with functionalities to support innovation.
1) xMAP technology;
2) PubMed portal; 3) xPONENT system or similar for reading and generation of a CSV file with results of the tests conducted; 4) Automation of the pipetting process; 5) EPM; 6) Teleconference.
Delay of the process 1) System to record lessons learned;
2) Knowledge management system.
1) Retention and dissemination of knowledge;
2) Velocity of the process.
1) Web tools for virtual collaboration;
2) Tele-interaction; 3) Laboratory information management system.
1) Agro-infiltration technology;
2) Sequencing; 3) Sequence analysis; 4) High throughput screening; 5) PubMed portal; 6) GenBank sequences bank; 7) Teleconference; 8) EPM.
Delay of the process 1) 1) Videoconference tool in the premises of Bio-Manguinhos;
2) Knowledge management system;
3) System to record lessons learned. The results show that Bio-Manguinhos makes a careful effort to choose partners to participate in the technological cooperation projects involved in the initial phases of the R&D process. The option for the "elite circle" collaboration mode, predominant in this state, is in agreement with the model proposed by Pisano & Verganti (2008) . However, even after acquiring the know-how, Bio-Manguinhos maintains the ties with the partners based on the belief that this option will accelerate the R&D process.
The evidence indicates that this option can be associated with the desire to speed up the R&D process, considering that the main acquisitions of raw materials, technologies and other inputs can be carried out directly by the partner, without the need to overcome the bureaucratic hurdles to which public-sector research organizations are subject in Brazil. The following comment reveals this concern:
I think that Bio-Manguinhos practices an elite circle... the inputs and raw materials can be purchased by the partner, enabling use to accelerate the process.
With respect to the ICTs identified in the literature examined, tele-interaction was present in all the technological collaboration projects studied, particularly those involving partners located outside of Brazil. Up to the date of the interviews, the teams of BioManguinhos basically used teleconferences. As can be seen in the following report, the unavailability of videoconference technology within Bio-Manguinhos caused negative impacts:
In particular, I have not had the opportunity to use videoconferences, but teleconferences were not very successful, because, as I said, I prefer to see instead of just hear the person with whom I'm exchanging ideas, because I can read the facial expressions.
In the absence of videoconference technology, some of the managers interviewed said they use MSN and Skype through their personal computers to exchange information, since the information security rules do not allow installing these programs in the organization's hardware. By resorting to this alternative, information recognized by the respondents themselves as confidential might be vulnerable. The alternative use of the communication platforms of partners causes inconveniences, as can be noted from the following comment:
If we could have videoconferences here in Bio-Manguinhos, our process would go faster. For you to have an idea, when we needed to hold a videoconference with GSK, we had to go to Jacarepaguá to use their room and equipment, and this took a lot of time.
At the time of the interviews, Bio-Manguinhos did not have any information system (IS) to support the recording and sharing of the information generated during the R&D process with external partners. This lack caused the managers to resort to a Windows folder called "Restricted" for this purpose. Even though the respondents alleged this folder served its objectives, the study showed that they also acknowledge that the ideal situation would be to have an IS applied to knowledge management, as reflected in the following comment:
Today we've learned a lot from exchanging internal information and have learned from experiments and from the errors of our colleagues, but we aren't that near to all the projects, so we haven't had an opportunity for internal exchange with all the program managers. If we had a database of knowledge and lessons learned it would be a dream come true.
It is important to point out that at the time of the survey Bio-Manguinhos had an ICT that could satisfactorily serve this function, the SharePoint software from Microsoft, a collaboration tool that is part of the Enterprise Project Management software package (EPM) acquired by the organization. EPM integrates a library of documents that, by means of SharePoint, can be shared over the web with external partners. To circumvent the limitation indicated by the above respondent, some project managers, repeating the practice already observed with other tools, said they used the SharePoint of external partners. This use considerably streamlined the exchange of information, and hence the speed of the project, as can be seen from the narrative below.
Even though acknowledging that the gains were only partial, the vice-director of the Technical Development area (TD) argued that it was necessary to change the internal culture of Bio-Manguinhos to create a solid and reliable base to permit use of SharePoint as a knowledge management tool for the projects conducted in collaboration with external partners:
In reality, people have adhered to and embraced this idea, of making this available to the project managers, program managers, external partners.... In the final analysis, we need to create this culture and use this tool better.
This narrative corroborates the evidence found in the literature that it is not sufficient just to adopt an ICT for it to work properly. It has to be implemented adequately, and organizational mechanisms must be created that stimulate people to capture the potential benefits of these technologies (KLEIN; SORRA, 1996) .
Bio-Manguinhos used, when applicable, high throughput screening (HTS) technologies in the R&D projects studied. In the yellow fever project, for example, this technology was used in the process of formulating the vaccine, when simultaneous tests of various substances were conducted at high speed to know which of them would best allow stabilizing the target protein. HTS was also used in the NAT project, which operated 24 hours a day, to enable analysis of 552 samples in just seven and a half hours. The evidence gathered demonstrated that the virtual collaboration web tool was also used in all the projects studied. Researchers often searched the PubMed portal to find bibliographical material, such as scientific articles, relevant to the projects under way in the organization. Among the advantageous uses of this tool, the following were mentioned: i) to discover if a project similar one being conducted by Bio-Manguinhos existed; ii) to carry out patent searches; iii) to find companies able to produce inputs relevant to projects; and iv) to learn the results of experiments carried out by other researchers that might contribute to the R&D projects of Bio-Manguinhos.
The R&D area of Bio-Manguinhos relies intensively on this ICT to consult the cell sequence database called the GenBank, present at the PubMed portal. By means of this module, the researchers search for sequences that can be sent to specialized companies (contract research organizations -CROs), to engage them to synthesize and supply primers for genetic sequencing to the R&D team. Besides downloading the sequences, the researchers upload to the GenBank the sequences discovered internally or by other molecular biology partner laboratories.
The evidence obtained shows that computational systems for experimentation were used in the yellow fever, dengue and NAT projects. In these efforts, this ICT was applied for viral sequencing and also to compare the sequences generated by the internal R&D team and those synthesized by specialized firms, like CROs. However, in the case of genome sequencing, which requires more complex computer processing, due to the lack of adequate infrastructure, Bio-Manguinhos resorted to other platforms of FIOCRUZ, and in some cases, outside the FIOCRUZ campus.
Virtual prototyping and visualization also were used by Bio-Manguinhos at the time of the survey. For example, the R&D team of the yellow fever project visualized and analyzed the three-dimensional structures of the protein of the virus by using a specific tool for sequence analysis containing complex mathematical algorithms. Another example was the dengue project, which used this ICT to analyze the sequences by phylogeny. To carry out these analyses, Bio-Manguinhos used specific free computer programs, some available from websites (such as www.nvbi.nlm.nih.gov). These programs allowed uploading a sequence defined by the researcher to a database of the provider for remote processing.
At the time this study was carried out, the LATAM of Bio-Manguinhos was developing monoclonal and polyclonal antibodies to meet the needs of internal and external researchers.
These biological materials were stored in a biological material bank (BMB), managed by and ii) the origin of the demand and the name of the project for which the they are used.
Recognizing the importance of the knowledge provided by the IT area, the respondents stated that other modules would be implemented to expand the scope of the system. The TD (technological development) area also intends to integrate it with the project management software (EPM) to allow researchers to plan the use of biological materials related to the activities of projects.
When the R&D projects analyzed here required more complex genome sequencing, To have access to these laboratories, Bio-Manguinhos signed "letters of commitment"
with them, a type of contract between governmental entities that authorizes the transfer of public funds. As reported in several of the interviews, and subsequently ratified by the vicedirector for DT, Bio-Manguinhos did not internally carry out more complex genome sequencing experiments, based on a policy that this was not its focus. If this reality were to change, the vice-director expressed the belief that it would not be necessary to create a bioinformatics laboratory, since the organization could opt to form a partnership with a specialized laboratory. be affirmed that this situation is partly due to the lack of knowledge exhibited by the researchers about the potential contribution of corporate ICTs.
CONCLUSION
The objective of this article was to identify and discuss the contribution of ICTs to the technological cooperation projects of Bio-Manguinhos. The results of the study show that the partnerships established by the organization contributed decisively to accelerate the projects analyzed, overcoming to some extent the restrictions imposed on public R&D centers in
Brazil. The preferential adoption of the "elite circle" mode to get around these constraints, in circumstances that would justify the substitution of this mode by other more flexible modes of collaboration, can be associated with the still predominant concern within the organization regarding control of IP. The study also showed that Bio-Manguinhos does not have a structured knowledge management system, posing serious limitations on the interaction of the internal R&D teams We believe this study makes relevant contributions to administrative theory and practice. In theoretical terms, the study expands the existing knowledge by demonstrating the relevance of deeper research into the use of ICTs to support management of technological collaboration in highly complex organizational contexts, as is the case of pharmaceutical companies. From the practical standpoint of management of science, technology and innovation (CT&I), the study allows managers of R&D projects that involve biotechnology, especially those associated with Brazilian public-sector pharmaceutical organizations, to make more effective use of the available ICTs.
The study brings further evidence that molecular biology has become an area of knowledge that relies heavily on information technologies, so closer approximation between the two fields is important. Because of the nature of the R&D processes in the pharmaceutical industry, great benefits can be gained from more thorough integration between the corporate R&D and IT areas, particularly if the organization in question has its own bioinformatics or computational biology area. The results also make it clear that the rules on access to and security of information of the R&D area should not be the same as those for the other areas of the organization.
In closing, we believe that in a scenario of growing use of cloud computing, web services and software as a service (SaaS), the contribution of a company's IT area should be increasingly directed to its specific business objectives. The results of this case study reveal that if the IT area is suffocated by administrative demands with transnational character, leaving insufficient time and inadequate training to explore the reality of the typical processes of the R&D area, this can seriously impair the ability to innovate in organizations involved in the life sciences.
